3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology

3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology

Opioids and benzodiazepines are fundamental components of balanced anesthesia and conscious sedation. Mastery of their receptor interactions, organ-system effects, active metabolites, and emergency reversal pharmacology is critical for the practicing CRNA.

---

1. Opioid Receptor Classification and Intracellular Signaling

Opioids exert their pharmacologic actions by binding to stereospecific, 7-transmembrane G-protein coupled receptors ($G_i/G_o$) located throughout the central nervous system (periaqueductal gray, locus coeruleus, rostral ventral medulla, dorsal horn substantia gelatinosa) and peripheral sensory nerve terminals.

Intracellular Signal Transduction

1. Inhibition of Adenylyl Cyclase: Decreases intracellular cyclic adenosine monophosphate ($cAMP$) synthesis.
2. Presynaptic Inhibition: Closes voltage-gated N-type calcium ($Ca^{2+}$) channels on primary afferent terminals, preventing exocytosis of excitatory neurotransmitters (Substance P, glutamate, calcitonin gene-related peptide [CGRP]).
3. Postsynaptic Inhibition: Opens G-protein coupled inwardly rectifying potassium ($K^+$) channels ($GIRK$), causing potassium efflux, membrane hyperpolarization, and resistance to excitatory transmission.

Opioid Receptor Subtypes & Physiological Actions

---

2. Comparative Clinical Potencies & Physicochemical Profiles

Pharmacokinetic Insights

• Alfentanil's Rapid Onset: Although less potent and less lipid-soluble than fentanyl, Alfentanil has the fastest onset of peak effect (~1.4 minutes) among traditional synthetic opioids because its $pK_a$ (6.5) is well below physiologic pH (7.4), rendering 89–90% of the drug in the un-ionized, diffusible form capable of rapidly crossing the blood-brain barrier.
• Morphine's Slow CNS Penetration: Low lipid solubility, high ionization at pH 7.4 (77% ionized), and slow crossing of the blood-brain barrier result in a delayed peak analgesic effect (15 to 30 minutes) after IV bolus administration. Histamine release from mast cells produces peripheral vasodilation, hypotension, and localized urticaria along the vein.

---

3. Unique Opioids: Metabolism & Active Metabolites

Morphine Metabolites & Renal Failure Hazard

Morphine undergoes extensive hepatic glucuronidation by UGT2B7 into two active metabolites:

1. Morphine-6-Glucuronide (M6G): Possesses potent $\mu$-opioid analgesic and respiratory depressant activity (up to 100-fold more potent than parent morphine at the CNS $\mu$-receptor). Excreted exclusively by the kidneys.
2. Morphine-3-Glucuronide (M3G): Devoid of analgesic activity; acts as a neuroexcitant causing allodynia, myoclonus, and hyperalgesia.

• Renal Failure Danger: In patients with renal failure (ESRD / oliguria), M6G accumulates rapidly, crossing the blood-brain barrier and producing delayed, life-threatening narcosis and prolonged respiratory arrest days after standard doses. Avoid morphine in renal failure; Hydromorphone or Fentanyl is preferred.

Meperidine & Normeperidine Toxicity

• Metabolism: Hepatically demethylated to normeperidine, which has half the analgesic potency but twice the neurotoxic/convulsant potency of parent meperidine ($t_{1/2} = 15-30\text{ hours}$, renal clearance).
• Toxic Manifestations: Normeperidine accumulation causes central nervous system irritability: myoclonus, muscle tremors, hyperreflexia, and grand mal seizures (especially in renal impairment or with patient-controlled analgesia >48 hours).
• Serotonin Syndrome Interaction: Meperidine acts as a weak serotonin reuptake inhibitor. Co-administration with Monoamine Oxidase Inhibitors (MAOIs), SSRIs, or TCAs can trigger fatal Serotonin Syndrome (Type 1 excitatory form): hyperpyrexia, severe hypertension, autonomic instability, muscle rigidity, coma, and death.
• Clinical Utility: First-line agent for postoperative shivering (25–50 mg IV), mediated via $\kappa$-receptor stimulation.

Remifentanil (Ester Hydrolysis)

• Structure: Piperidine opioid containing a methyl ester linkage on the piperidine ring.
• Metabolism: Rapidly hydrolyzed by non-specific blood and tissue esterases into an inactive carboxylic acid metabolite (GR90214, 1/4600th potency of parent compound, excreted renally).
• Pharmacokinetic Independence: Metabolism is entirely independent of hepatic and renal function, and is unaffected by pseudocholinesterase (butyrylcholinesterase) deficiency.
• Context-Sensitive Half-Time: Remains constant at 3 to 4 minutes regardless of whether the infusion runs for 15 minutes or 12 hours. Rapid offset mandates proactive administration of longer-acting transition analgesics (e.g., hydromorphone, fentanyl, methadone) prior to emergence.

---

4. Adverse Opioid Syndromes

Acute Chest Wall Rigidity ("Wooden Chest Syndrome")

• Etiology: Rapid, high-dose IV boluses of lipophilic synthetic opioids (fentanyl, sufentanil, remifentanil, alfentanil).
• Mechanism: Centrally mediated via $\mu$-receptor activation in the substantia nigra, corpus striatum, and nucleus raphe pontis, increasing dopaminergic outflow and spinal motor neuron excitability.
• Presentation: Sudden severe rigidity of thoracic and abdominal musculature, accompanied by glottic closure and vocal cord spasm, rendering mask ventilation and bag-valve-mask manual ventilation impossible.
• Definitive Treatment: Administer a rapid-acting neuromuscular blocking agent (Succinylcholine 1.0 mg/kg or Rocuronium 1.0 mg/kg) to immediately relax skeletal muscle and allow endotracheal intubation, or titrate Naloxone (if muscle relaxation is not feasible).

Opioid-Induced Hyperalgesia (OIH)

• Definition: A state of paradoxical nociceptive sensitization caused by exposure to opioids (most frequently seen after high-dose remifentanil infusions), where the patient perceives increased pain intensity to standard noxious stimuli or allodynia to non-noxious stimuli.
• Mechanism: Activation of central NMDA glutamate receptors, spinal cord dynorphin release, and neurokinin-1 activation.
• Prevention & Treatment: Co-administration of low-dose ketamine (0.2–0.5 mg/kg bolus or 2–5 mcg/kg/min infusion), magnesium sulfate, $\alpha_2$-agonists (dexmedetomidine), and multimodal non-opioid analgesia.

5. Benzodiazepines & Reversal with Flumazenil

Mechanism of Action

Benzodiazepines bind stereospecifically to the benzodiazepine receptor recognition site located at the interface of the $\alpha$ and $\gamma$ subunits of the pentameric $GABA_A$ receptor complex. Unlike barbiturates, benzodiazepines do not directly gate chloride channels; they act as allosteric modulators to increase the frequency of chloride channel opening in the presence of GABA, enhancing hyperpolarizing inhibitory postsynaptic potentials.

Comparative Pharmacology of Benzodiazepines

Flumazenil (Romazicon)

• Mechanism: Competitive antagonist at the benzodiazepine binding site on the $GABA_A$ receptor. Completely displaces agonists, inverse agonists, and partial agonists without intrinsic allosteric efficacy.
• Dosing Protocol: Initial dose 0.2 mg IV over 15 seconds. If no response after 60 seconds, administer 0.1 to 0.2 mg every 60 seconds titrated to clinical effect (maximum cumulative dose: 1.0 mg).
• Pharmacokinetics & Resedation Risk: Elimination half-life is 45 to 60 minutes. Because the half-life of flumazenil is substantially shorter than midazolam (1.5–2.5h), lorazepam (10–20h), and diazepam (20–50h), the patient is at high risk for recurrent sedation and respiratory depression (resedation) once flumazenil is metabolized. Monitor patient in PACU for at least 2 hours.
• Black Box Warnings / Absolute Contraindications:
  1. Chronic Benzodiazepine Tolerance / Physical Dependence: Can precipitate severe, acute withdrawal syndrome including intractable status epilepticus and autonomic storm.
  2. Concurrent Tricyclic Antidepressant (TCA) Overdose: Benzodiazepines suppress TCA-induced ventricular dysrhythmias and seizures; flumazenil unmasks TCA toxicity, causing fatal arrhythmias, refractory seizures, and asystole.

---

6. Opioid Antagonists: Naloxone Pharmacology & Hazards

Naloxone (Narcan)

• Mechanism: Pure competitive antagonist at $\mu, \kappa, \text{ and } \delta$ opioid receptors, with highest affinity for the $\mu$-receptor. Lacks any intrinsic agonist activity.
• Titration Protocol: Dilute one ampule (0.4 mg / 1 mL) with 9 mL normal saline to achieve a concentration of 0.04 mg/mL (40 mcg/mL). Administer 20 to 40 mcg (0.5–1.0 mL) IV every 2 minutes, titrating carefully until adequate spontaneous ventilation and airway protection return without abruptly reversing baseline surgical analgesia.
• Duration vs. Renarcotization: Elimination half-life is 30 to 90 minutes (mean ~60 minutes). This is significantly shorter than all common therapeutic opioids (morphine $t_{1/2} = 2-3\text{h}$, hydromorphone $2-3\text{h}$, fentanyl $3-4\text{h}$, methadone $24-36\text{h}$). As naloxone concentrations decline below receptor occupancy thresholds, the patient can relapse into severe narcosis, hypoventilation, and fatal respiratory arrest (renarcotization). Mandatory PACU observation for $\ge 2\text{ hours}$ is required.
• Hazards of Rapid / High-Dose Bolus Reversal: Sudden, complete opioid antagonism unmasks severe surgical pain and precipitates an explosive massive sympathetic nervous system surge mediated by endogenous catecholamine release:
  • Severe hypertension and malignant tachyarrhythmias (ventricular tachycardia, ventricular fibrillation)
  • Flash non-cardiogenic pulmonary edema: Massive central sympathetic venoconstriction shifts systemic blood volume into the low-resistance pulmonary vascular bed, generating hydrostatic pulmonary capillary hypertension and capillary endothelial shear stress
  • Myocardial ischemia and acute cardiac arrest